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Background: Multiple immunotherapy approaches have improved adaptive anti-tumor immune responses in
patients with early stage disease; however, results have been less dramatic when treating patients with late stage
disease. These blunted responses are likely due to a host of factors, including changes in the tumor
microenvironment and systemic immunosuppressive features, which accompany advanced tumor states. We
hypothesized that cytoreductive surgery could control these immunosuppressive networks and restore the potency
of immunotherapy in advanced disease scenarios.
Methods: To test these hypotheses, two representative intratumoral immunotherapies (an adenoviral vector
encoding a suicide gene, AdV-tk, or a type-I interferon, Ad.IFNα) were tested in murine models of lung cancer.
Cytoreductive surgery was performed following treatment of advanced tumors. Mechanistic underpinnings were
investigated using flow cytometry, in vivo leukocyte depletion methods and in vivo tumor neutralization assays.
Results: AdV-tk and Ad.IFNα were effective in treating early lung cancers, but had little anti-tumor effects in late
stage cancers. Interestingly, in late stage scenarios, surgical cytoreduction unmasked the anti-tumor potency of
both immunotherapeutic approaches. Immune mechanisms that explained restoration in anti-tumor immune
responses included increased CD8 T-cell trafficking and reduced myeloid derived suppressor cell populations.
Conclusion: This study demonstrates that surgical resection combined with immunotherapy may be a rational
therapeutic option for patients with advanced stage cancer.
Keywords: Surgical oncology, Immunotherapy, Cancer, Animal modelBackground
A number of intratumoral immunotherapies are cur-
rently being examined in clinical trials [1,2]. In these
trials, limited success has been observed in patients with
advanced tumor burdens [3]. Potential reasons for the
lack of effectiveness of intratumoral immunotherapy in
advanced cancer states include the development of com-
plex immunosuppressive features: (i) low CD8 T-cell to
tumor ratio [4], (ii) extensive systemic suppressive cell
populations such as myeloid derived suppressor cells* Correspondence: sunil.singhal@uphs.upenn.edu
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reproduction in any medium, provided the or(MDSCs) [5] and T-regulatory cells [6], (iii) poor T-cell
trafficking into the tumor [7], (iv) an immunosuppres-
sive tumor microenvironment [8], and (vi) increased
levels of soluble immunosuppressive substances such as
prostaglandin E2 [9], TGF-β [10], VEGF [11] or IL-10
[12,13].
Interestingly, several years ago our group made the ob-
servation that immunotherapy (in the form of Ad.IFNβ)
was effective in treating very large mesothelioma tumors
when therapy was followed by a complete surgical removal
[14]. These findings were reproduced by Grinshtein and
colleagues who also demonstrated increased immunother-
apy potency when combined with surgery in a neoadjuvant
(pre-operative) setting [15]. Although these findings arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these observations have not been elucidated.
In this study, we further develop this concept of
neoadjuvant immunotherapy followed by surgical cytore-
duction. Two representative intratumoral immunother-
apies currently in clinical trials were chosen to test the
hypothesis. One approach utilizes a replication-defective
adenoviral vector encoding for the HSV.tk protein
(AdV-tk) in combination with ganciclovir (GCV). The
HSV.tk gene monophosphorylates anti-herpetic pro-
drugs, such as GCV, that are further phosphorylated by
endogenous cellular kinases into active triphosphate nu-
cleotide analogs. These analogs are incorporated into
cellular DNA, which results in an immunogenic cell
death [16]. The second approach utilizes the intratu-
moral delivery of a replication-deficient adenoviral vec-
tor encoding for the type-I interferon, interferon-α (Ad.
IFNα). Type-I interferons stimulate the immune system
and have antitumor activity that includes immunoregula-
tory effects on antibody production, natural killer (NK)
and T-cell activation, macrophage function, delayed-type
hypersensitivity, and MHC antigen expression, in addition
to anti-angiogenic properties and anti-proliferative effects
[17]. We utilized two models of cytoreductive surgery
which generate either local recurrences (partial tumor re-
section) or systemic recurrences (spontaneously metastatic
cell lines with complete primary site resection).
We found that intratumoral immunotherapies are suc-
cessful in treating limited disease by generating robust
anti-tumor responses, but fail with increasing tumor
burden despite generating anti-tumor immunocytes.
Surgical cytoreduction restores the anti-tumor effects of
immunotherapy by decreasing systemic MDSC popula-
tions, thus allowing enhanced CD8 T-cell trafficking and
function. These data provide further support the paradigm
of combining immunotherapy with surgical cytoreduction
and provide one potential explanation for its additive
effects.
Results
Intratumoral immunotherapy is effective in treating small
tumors due to generation of anti-tumor CD8 T-cells
The anti-tumor effectiveness of intratumoral immuno-
therapy was first investigated using gene-mediated cyto-
toxic immunotherapy (GMCI) in early stage TC1 lung
cancer flank tumors. Once tumors were established and
measured ~250 mm3, animals were randomized to treat-
ment with a single intratumoral injection of AdV-tk or
Ad.LacZ. After 48 hours, both groups were treated with
the prodrug GCV for five days. Mice randomized to
AdV-tk/GCV were found to have significantly reduced
tumor progression; p = 0.03 (Figure 1A). We similarly
examined the anti-tumor effects of intratumoral cytokine
immunotherapy as a treatment for early TC1 tumors usingAd.IFNα (or Ad.LacZ as control). Again, there were dra-
matic decreases in tumor volume in mice randomized to
cytokine gene therapy; p = 0.009 (Figure 1A).
We next sought to determine if AdV-tk/GCV gener-
ates anti-tumor CD8 T-cells. To do this, we assayed
splenic cytotoxic T lymphocytes using an in vivo tumor
neutralization assay. To perform this assay, fresh TC1
tumor cells were mixed with CD8 T-cells isolated from the
spleens of tumor-bearing mice treated with AdV-tk/GCV
or Ad.LacZ/GCV; this mixture was then injected into
tumor-naïve mice. When compared to controls, we
observed significantly decreased tumor volume of tumors
grown in the presence CD8 T-cells isolated from spleens
of mice receiving GMCI; p = 0.01 (Figure 1C). To further
demonstrate the key functional role of effector CD8 T-
cells in AdV-tk/GCV treatment, CD8 T-cells were
depleted with an anti-CD8 T-cell antibody prior to and
during GMCI administration. Flow cytometric analysis
confirmed CD8 T-cell depletion in our experimental
groups (Additional file 1: Figure S1). We found that select-
ive elimination of CD8 T-cell populations negated the
effects of GMCI protocols in animals bearing TC1 flank
tumors; p= 0.006 (Figure 1D).
Intratumoral immunotherapy has little effect in treating
advanced tumor burden despite generating anti-tumor
CD8 T-cell responses
To more closely model advanced human cancers, we uti-
lized two models of advanced disease: large established
flank tumors (locally advanced disease) and spontan-
eously metastatic tumors (metastatic disease). To
examine the anti-tumor potential of intratumoral im-
munotherapy in locally advanced disease, mice bearing
large TC1 flank tumors (~700 mm3) were randomized to
intratumoral inoculations of Ad.LacZ, Ad.IFNα or AdV-
tk. After 24 hours, the mice treated with AdV-tk or Ad.
LacZ were injected daily with GCV for 5 days. In con-
trast to the responses in small tumors, intratumoral im-
munotherapy had negligible inhibitory effects on tumor
burden when administered in advanced tumors
(Figure 2A).
To further explore the effectiveness of immunother-
apy with regard to local tumor burden, we initiated
AdV-tk/GCV therapy when tumors reached various
sizes (200, 400, 600 and 800mm3) (Figure 2B). Although
small (200 mm3) tumors were very susceptible to immuno-
therapy, anti-tumor effects of AdV-tk/GCV diminished as
tumor size increased and eventually became completely in-
effective. Similar relationships have been previously
described when using type-I interferon cytokine gene ther-
apy (Ad.IFNβ therapy) in treating TC1 tumors [14].
We then focused on the scenario modeling metastatic
disease using the spontaneously metastatic NSCLC can-
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Figure 1 Intratumoral immunotherapy is effective in treating early lung cancer due to enhanced CD8 T-cell function. (A) AdV-tk/GCV
(n = 8) or Ad.LacZ/GCV (control) (n = 8) was administered intratumorally at Day 11 when TC1 tumors measured ~250 mm3, and volume was
recorded. AdV-tk/GCV provided a significant reduction in tumor volume. (B) Ad.IFNα (n = 8) or Ad.LacZ (control) (n = 8) was administered
intratumorally at Day 8 when tumors measured ~250 mm3, and volume was recorded. Ad.IFNα provided a significant reduction in tumor volume.
(C) CD8 T-cells form mice receiving AdV-tk/GCV were superior in neutralizing fresh tumor cells in vivo when compared to those CD8 T-cells
harvested from mice receiving Ad.LacZ/GCV (n = 5 per group). (D) Mice (n = 8 per group) bearing early TC1 tumors were randomized to four
treatment groups (i) AdV-tk/GCV, (ii) Ad.LacZ/GCV, (iii)AdV-tk/GCV and CD8 antibodies or (iv) Ad.LacZ/GCV and CD8 antibodies. Growth curves
were plotted. Mice receiving CD8 antibodies, regardless of co-treatment, grew rapidly and with similar growth kinetics. * Represents a p< 0.05,
** represents a p< 0.01, shaded bar designates time over which AdV-tk/GCV therapy took place.
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tumors reached the average size of 500 mm3 (Day 18),
intratumoral immunotherapy (Ad.IFNα, AdV-tk/GCV,
or Ad.LacZ/GCV) was begun. On day 42, after tumor
cell inoculation, a time when lung metastases are known
to exist, lungs were harvested, sectioned, and the surface
area of the lungs and surface nodules measured. Again,
we found no significant reduction in the percentage of
lung surface area involved with tumor burden at Day 42;
11.6% (Ad.LacZ/GCV), 11.0% (AdV-tk/GCV), and 10.9%
(Ad.IFNα); p = 0.76 (Figure 2C). Further, treatment did
not reduce the number of lung metastases (data not
shown).
Although no therapeutic benefit of AdV-tk and Ad.IFNα
was appreciated in these advanced tumor settings, previ-
ous work with Ad.IFNβ has suggests that immunotherapy
still generates CD8 T-cells capable of tumor neutralization
[14]. With this concept in mind, we evaluated the ability
of GMCI (AdV-tk/GCV) agents to generate cytotoxic
CD8 T-cells in animals bearing large tumors. We again
treated mice bearing locally advanced TC1 tumors
(~700mm3) with Ad.LacZ/GCV or AdV-tk/GCV. Three
days after GCV was completed, an in vivo tumorneutralization assay was performed by mixing TC1 tumor
cells with CD8 T-cells isolated from the spleens of the
aforementioned mice; this mixture was then injected into
naïve mice. Interestingly, CD8 T-cells from animals that
received AdV-tk/GCV therapy were more effective in
inhibiting tumor growth than the other control groups;
p = 0.03 (Figure 2D). This trend suggests that intratu-
moral immunotherapies are indeed able to generate
anti-tumor CD8 T-cells, but these populations are
inhibited by factors associated with advanced tumor
states.
Cytoreductive surgery restores the effectiveness of
immunotherapy in advanced tumor states
Given that intratumoral immunotherapies generate CD8
T-cells, yet fail to elicit clinical responses in bulky dis-
ease, we aimed to investigate the concept of “adjuvant
immunotherapy”. The concept is based on the premise
that surgical resection can restore the immunobiology to
that of a host with early disease—i.e. eliminate portions
of immunosuppression that accompany advanced tumor
states [18]. To test this hypothesis in locally advanced
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Figure 2 Intratumoral immunotherapy is ineffective in the setting advanced tumor burden, and but produces functionally enhanced
CD8 T-cells. (A) C57BL/6 mice bearing locally advanced TC1 tumors (~750mm3) were randomized to treatment with AdV-tk/GCV, Ad.IFNα or Ad.
LacZ/GCV (control) and tumor volume was recorded. No difference tumor growth was appreciated. (B) Mice (n = 5) bearing TC1 tumors of
varying sizes (200mm3, 400mm3, 600 mm3 and 800mm3) were treated with AdV-tk/GCV. Mice (n = 5) bearing tumors measuring 200mm3 were
treated with Ad.LacZ/GCV as a control. As can be seen, AdV-tk/GCV loses effectiveness as tumor burden increases as exemplified by tumor
volume at Day 22. (C) Mice bearing LKR tumors, a spontaneously metastatic NSCLC line, were treated with AdV-tk/GCV, Ad.IFNα or Ad.LacZ/GCV
(control) at a time point in which lung metastases are known to be present. Lungs were harvest at Day 42 and analyzed for tumor burden. Lung
surface area involved with tumor burden was compared, and no difference was appreciated among groups. (D) in vivo tumor neutralization assay
—Fresh TC1 tumor cells were mixed with (i) CD8 T-cells from mice receiving Ad.LacZ/GCV, (ii) CD8 T-cells form mice receiving AdV-tk/GCV and
(iii) CD8 T-cells from tumor naïve mice and mixed into mice (n = 5). TC1 tumor cells were injected alone to confirm tumor cell viability. Trends
toward enhanced CD8 T-cell function with intratumoral previous exposure were appreciated. * Represents a p< 0.05, ** represents a p< 0.01.
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treatment, mice in both groups underwent partial resec-
tion to model cytoreduction [19]. Surgical sites were
then monitored for recurrent disease. We found that
mice treated with neoadjuvant AdV-tk/GCV had signifi-
cantly decreased recurrent tumor burdens at all post-
operative time points when compared to those mice
randomized to control treatments; p = 0.006 (Figure 3A).
We repeated this approach using cytokine gene therapy
with Ad.IFNα and partial resection; again mice receiving
neoadjuvant therapy had reduced postoperative volumes;
p = 0.004 (Figure 3B).
This concept was next tested in the setting of advanced
metastatic disease using LKR. Once flank tumors became
established, mice were randomized to one of three treat-
ment protocols: (1) AdV-tk/GCV, (2) Ad.IFNα, or (3) Ad.
LacZ/GCV (control). Two days after treatments were
completed, mice underwent complete flank tumor exci-
sion. Lungs were harvested on Day 40, and metastatictumor burden was analyzed by assessing the percentage
of lung surface area involved with tumor burden. On
histologic analysis we found that those mice receiving
immunotherapy treatments (AdV-tk/GCV or Ad.IFNα)
had significant decreases in metastatic burden as com-
pared to controls; p< 0.01 in both circumstances
(Figure 3C).
Together these results suggest that intratumoral im-
munotherapy with cytoreduction surgery has the poten-
tial to be effective in treating advanced disease states.
Intratumoral immunotherapy increases intratumoral
trafficking and restores function of CD8 T-cells
Our data had suggested that a central mechanism of
GMCI lays in the generation of cytotoxic effector CD8 T-
cell populations. To investigate the functional effects of
combining cytoreductive surgery and immunotherapy in
restoring CD8 T-cell anti-tumor activity, we again per-




















































































Figure 3 Cytoreductive surgery restores effectiveness of immunotherapy even when administered in advanced tumor burden. (A) Mice
(n = 10) bearing large established tumors were randomized to AdV-tk/GCV or Ad.LacZ/GCV; two days following completion mice underwent
positive margin surgery. Recurrent flank tumors were observed. We observed dramatic decreases in recurrent tumor volumes in those mice
receiving neoadjuvant AdV-tk/GCV. (B) Similarly, mice (n = 10) bearing established tumors were randomized to Ad.IFNα or Ad.LacZ, followed by
partial resection surgery 3 days later. Again, recurrent tumors were decreased in mice receiving intratumoral immunotherapy protocols. (C) We
next tested this approach in the setting of metastatic disease. Mice (n = 14) bearing established LKR tumors were administered AdV-tk/GCV or Ad.
LacZ/GCV at a time when metastatic lesions were known to be present. Two days after completion of drug administration, complete tumor
excision was completed. On Day 40 of the experiment, lung tumor burden was assessed. Mice randomized immunotherapy had significantly less
metastatic disease as compared to mice receiving control treatment. * Represents a p< 0.05, ** represents a p< 0.01.
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of four groups: (1) Ad.LacZ/GCV, (2) AdV-tk/GCV, (3)
Ad.LacZ/GCV with cytoreduction, and (4) AdV-tk/GCV
with cytoreduction. CD8 T-cells were purified from sple-
nocytes five days after the third and fourth groups under-
went surgery, and were then mixed with fresh TC1 tumor
cells. This mixture was then injected into the flanks of
tumor naïve mice. After 9 days of tumor growth, we found
that CD8 T-cells harvested from mice receiving both
AdV-tk/GCV and cytoreductive surgery inhibited tumor
growth more potently than CD8 T-cells from other treat-
ment groups; p = 0.02 (Figure 4A).
To examine CD8 T-cell trafficking after surgery, we
performed immunohistochemistry staining for CD8 T-
cells in recurrent TC1 tumors of mice that were ran-
domized to AdV-tk/GCV or Ad.LacZ/GCV (groups 3
and 4 from the previous experiment). Immunohisto-
chemical staining demonstrated increased populations
of CD8 T-cells in tumors of mice receiving AdV-tk/
GCV compared to Ad.LacZ/GCV; 2.4% vs. 0.8% of
total cells; p = 0.03 (Figure 4B).
This data demonstrates that the combination of im-
munotherapy and surgery have additive effects inaugmenting effector CD8 T-cell population function and
infiltration.
Myeloid derived suppressor cells and immunosuppressive
cyotkines are associated with advanced tumor burden
Advanced tumor states are associated with intricate im-
munosuppressive networks that subsequently impair
anti-tumor effects of CD8 T-cells. Myeloid derived sup-
pressor cells (MDSCs), which are defined as CD11b+Gr1+
cells in mice [18,20], are one such group. We were inter-
ested to see if cytoreduction decreased systemic
MDSCs, as hypothesized by other groups [18,20]. To
evaluate this concept, mice bearing large TC1 tumors
were randomized to sham surgery or partial resection.
At postoperative Day 3, mice were sacrificed and
spleens were evaluated for MDSCs populations using
flow cytometry; spleens from tumor naïve mice were
also analyzed. We appreciated a significant increase in
systemic MDSCs (as a fraction CD45 splenocytes) in
mice bearing large tumors as compared to tumor-naïve
mice; 4% to 18.6%; p< 0.01 (Figure 5A-top panel). Fur-
ther, within three days of surgical cytoreduction, the







TC1 Naïve Ad.LacZ tk-AdV Surgery Combo
TC-1 Cells + + + + + +
Naïve CD8+ T-Cells - + - - - -
CD8+ T-Cells after 
Ad.LacZ - - + - - -
CD8+ T-Cells after 
AdV-tk - - - + - -
CD8+ T-Cells after 
Surgery - - - - + -
CD8+ T-Cells after
AdV-tkAND
Surgery - - - - - +
Figure 4 Intratumoral immunotherapy prior to surgery is effective due to enhanced CD8 T-cell function. (A) in vivo tumor neutralization
assay. Mice bearing established flank tumors were randomized to one of four groups: (i) Ad.LacZ/GCV, (ii) AdV-tk/GCV, (iii) Ad.LacZ/GCV with
cytoreduction surgery, and (iv) AdV-tk/GCV with cytoreduction surgery. CD8 T-cells were mixed with fresh tumor cells and injected into tumor
naïve mice. After 9 days of tumor growth, we found that CD8 T-cells harvested from mice receiving AdV-tk/GCV and cytoreductive surgery
inhibited tumor growth more potently than CD8 T-cells from other treatment groups. (B) Immunohistochemistry images of representative tumor
from mice receiving AdV-tk/GCV or Ad.LacZ/GCV. Specimens were stained using anti-CD8 antibodies.
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note, there was an increase in the proportion of gran-
ulocytic MDSCs (Ly6GhiLy6Cmod of total MDSCs) in
mice bearing large tumors as compared to tumor naïve
mice (44.6% vs. 71.3.7%; p = 0.01) (Figure 5A-middle
panel). Following cytoreduction the percentage of gran-
ulocytic MDSCs decreased to near tumor-naïve levels
(71.3% vs. 54.3%; p = 0.02) (Figure 5A-middle panel). Fi-
nally, we appreciated similar trends with regard to the
percentage of macrophages (CD11b + F4/80+) of total
splenic leukocytes: we observed an increase from 2.2%
in tumor naïve mice to 5.4% in mice bearing large
tumors (p = 0.02); following surgical resection the per-
centage of macrophages decreased to 2.3% (p = 0.02)
(Figure 5A-bottom panel). These results suggest that
reductions in immunosuppressive myeloid cells may be
a mechanism by which CD8 T-cell function is restored
following tumor cytoreduction.
We also focused on the serum presence of two im-
munosuppressive cytokines associated with MDSC
generation and function (G-CSF and IL-6). Similar to
cellular trends, mice bearing large primary tumors
had significantly increased levels of both cytokines
when compared to tumor naïve mice (Figure 5B).
More specifically, we appreciated nearly a 60-fold in-
crease of G-CSF (p< 0.001) and a 20-fold increase of
IL-6 (p< 0.001). Following cytoreduction, serum levels
of these immunosuppressive cytokines returned to
baseline levels.Together these finding demonstrate that advanced
tumor states are associated with both increased cellular
immunosuppressive populations, namely MDSCs, and
elevated immunosuppressive cytokine levels. Further,
surgical resection eliminates both of these factors.
MDSCs are responsible for blunting the efficacy of
intratumoral immunotherapy
To confirm that MDSC populations inhibit activated
CD8 T-cells in advanced tumor states, we performed a
“mixing” in vivo tumor neutralization assay. Mice bear-
ing small primary tumors were treated with AdV-tk/GCV
(a time when GMCI generates CD8 T-cells with potent
anti-tumor potential). From these mice, splenic CD8 T-
cells were purified and mixed with fresh TC1 tumor
cells and various CD11b populations (i. from tumor
naïve mice, ii. from mice bearing large primary tumors
or iii. mice which had undergone cytoreductive sur-
gery). Cells were mixed at a tumor:CD8 T-cell:CD11b
ratio of 1:3:10. These suspensions were injected into the
flanks of tumor naïve mice and growth was monitored
for 10 days. We noted that the presence of CD11b+cells
isolated from mice bearing large tumors significantly
blunted CD8 T-cell tumor neutralizing capabilities as
compared to myeloid cells obtained from tumor naïve
mice (p = 0.008) and mice undergoing surgery (p = 0.02)
(Figure 6).
These findings provide in vivo evidence that increased
MDSC populations associated with advanced tumor



























































Figure 5 Myeloid derived suppressor cells associated with advanced tumor burden are responsible for blunting immunotherapy
potency. (A) Flow cytometry of splenocyte populations obtained from (i) tumor naïve mice, (ii) mice bearing large, establish TC1 tumors or (iii)
mice 3 days status post partial resection. Top-panel—Myeloid derived suppressor cells (CD11b+ Gr1+) were compared. MDSCs increased with
tumor growth, but were found to be eliminated following cytoreduction surgery. Middle-panel—Granulocytic MDSCs (Ly6GhiLy6Cmod) were also
compared; and increased with tumor growth, but were found to be eliminated following cytoreduction surgery. Bottom-panel—Splenic
macrophages (Cd11b+F4/80+) increased with tumor growth were found to be eliminated following cytoreduction surgery. (B)
Immunosuppressive cytokines (G-CSF and IL-6) in mouse serum at various times as measured by ELISA. Maximum levels were found in large
tumors; surgical cytoreduction significantly decreased these cytokines to normal levels. * Represents a p< 0.05, ** represents a p< 0.01.
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ther, these findings support the hypothesis that surgery
restores potency of CD8 T-cells via MDSC elimination.
Discussion
The results of this study extend the concept of coupling
cytoreductive surgery with neoadjuvant immunotherapy
to restore the effectiveness of immunotherapy. To dem-
onstrate this, we used two representative intratumoral
immunotherapies which are currently being evaluated in
clinical trials: an adenoviral vector encoding herpes sim-
plex thymidine (AdV-tk) [1] and an adenoviral vector
delivering the gene for interferon-α (Ad.IFNα) [2]. These
immunotherapies have been effective in treating small
tumors by CD8 T-cell dependent mechanisms. In con-
trast, as previous clinical data suggests, we found thatimmunotherapies had little anti-tumor effect in the set-
ting of advanced disease. We demonstrate that this fail-
ure is not due to the inability of these therapies to
generate CD8 T-cells, but the results of CD8 T-cell ac-
tivity and trafficking. Although many mechanisms may
result in impaired CD8 T-cell responses in large tumors
(systemic immunosuppression, poor intratumoral vascu-
larity, rapid tumor growth kinetics), we chose to focus
on tumor associated immunosuppression (MDSCs).
We postulated that reducing the tumor burden would
minimize the immunosuppressive networks, thus pro-
viding an opportunity for generated CD8 T-cells to
neutralize tumor cells. We found that after cytoreducing
large tumors, immunotherapies inhibited the rapid
growth of both locally recurrent disease and systemic
































TC-1 Cells + + + +
CD8* + Naïve CD11b - + - -
CD8* + Tumor CD11b - - + -
CD8* + Post-Surgery     
CD11b - - - +
*
*all CD8 T-cells were obtained from mice bearing small 
primary tumors  and receiving AdV-tk (highly activated 
CD8 T-cells)
**
Figure 6 (A) Mixing in vivo tumor neutralization assay:
Functionally active CD8 T-cells (obtained from spleens of mice
bearing small primary tumors and after AdV-tk/GCV treatment) were
mixed with fresh TC1 tumor cells and CD11b+ populations obtained
at different points during progression: (i) tumor naïve mice, (ii) mice
bearing large primary tumors or (iii) three days after surgical
cytoreduction. Growth was then monitored for 10 days.* Represents
a p< 0.05, ** represents a p< 0.01.
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increased trafficking and enhanced anti-tumor function.
We appreciated that surgical cytoreduction significantly
decreased the quantity of immunosuppressive MDSCs, a
group cells associated with impaired adaptive immune
responses [18,20].
In addition to supporting previous reports, this study
expands on this the concept of a synergy between im-
munotherapy and surgery. First, we incorporate more ac-
curate cancer surgery models in which disease predictably
and spontaneously recurs locally or distantly. These
approaches better mimic the human cancer scenario as
compared to previous models that commonly include
“rechallenging” with a second tumor cell inoculum follow-
ing primary tumor resection [14]. Secondly, we begin to
elucidate the mechanistic underpinnings which may ex-
plain the success of combining immunotherapy with sur-
gical cytoreduction (i.e. loss of MDSC). Our data supports
previous findings that immunosuppressive myeloid cells
accumulate during tumor progression and contribute to
immunosuppression by inhibiting the function of CD8 T-
cells via immunosuppressive cytokine production (namely
IL-6 and G-CSF), generation of oxygen radicals, and close
cell-to-cell interactions [21]. It is likely that the CD8 T-cell generated by intratumoral immunotherapies are also
subject to such effects. We have become encouraged by our
findings and have developed a strong interest in pursuing a
clinical trial which combines neoadjuvant immuno-gene
therapy utilizing Ad.IFNα for malignant mesothelioma.
We demonstrate that surgery is a provocative mechan-
ism to increase intratumoral immunotherapy potency.
However, other approaches, including increasing vector
dosage and frequency, are also reasonable solutions. Al-
though feasible, previous evidence has shown only few
cells actually need to be infected due to “bystander
effects” [22], thus unnecessary dose escalation may also
needlessly introduce harmful side-effect profiles.
There are important limitations to this report due to
our syngeneic models of flank tumors. To date, xeno-
graft models and orthotopic tumors originating from
transgenic advances have emerged as gold-standard
approaches to study cancer biology and therapeutics.
The difficulty with such approaches in evaluating the po-
tential synergy between immunotherapy and surgery is
that xenograft models are established in immunodefi-
cient hosts while orthotopic models typically arise in
locations that are not amenable to surgical excision.
Given these hurdles we believe that flank tumor ap-
proach at least provides a scenario approximating the
clinical scenario. Further, we attempt to incorporate a
model where metastatic recurrences are found in the
lungs, thus mirroring the clinical scenario of distant me-
tastasis after surgery.
Conclusions
In summary, intratumoral immunotherapy is an appeal-
ing approach to treat cancers, however, to date it has
had limited success in advanced disease states. Our
study strengthens the concept of using in situ neoadju-
vant immunotherapy approaches in patients with
advanced tumor burden. The benefits of surgery and im-
munotherapy go beyond simple mechanical cytoreduc-
tion, and suggest a more complex interplay of
immunological principles. We believe that with proper
collaboration and further investigation, this multidiscip-
linary approach has the potential to have tremendous
impacts that may be applicable to patients diagnosed
with a variety of malignancies.
Methods
Animals
Female C57BL/6 mice (B6, Thy1.2) were purchased from
Charles River Laboratories. Female C57BL/6J x 129P3/J
hybrids (B6-129/J1) were purchased from The Jackson
Laboratory. All mice were maintained in pathogen-free
conditions and used for experiments at ages 8 week or
older. Recognized principles of laboratory animal care
(NIH publication No.85-23, revised 1985) were followed
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pital of Philadelphia, the Wistar Institute and the Uni-
versity of Pennsylvania approved all protocols.
Cell lines
TC1 cells were derived from mouse lung epithelial cells of a
C57BL/6 mouse, immortalized with human papillomavirus
(HPV)-16 E6 and E7, and transformed with the c-Ha-ras
oncogene {Lin, 1996 #1000}. The murine lung cancer line
LKR was derived from an explant of a pulmonary tumor
from an activated Kras G12D mutant mouse that had been
induced in an F1 hybrid of 129Sv.J and C57BL/6 [23].
These cells were authenticated by morphologic, cell prolif-
eration, and Mycoplasma tests, as recommended in ATCC
Technical Bulletin No. 8 (2007).
TC1 cells were maintained in R10 media (RPMI sup-
plemented with 10% heat-inactivated fetal bovine serum,
1% glutamine, and 1% penicillin and streptomycin (P/S))
and cultured at 37°C in a humidified incubator contain-
ing 5% CO2. LKR was maintained in D10 media (DMEM
supplemented with 10% heat-inactivated fetal bovine
serum, 1% glutamine, and 1% penicillin and strepto-
mycin (P/S)) and cultured at 37°C in a humidified incu-
bator containing 5% CO2.
Vectors
The non-replicating serotype 5 adenovirus containing
the herpes simplex virus thymidine kinase gene driven
by a Rous sarcoma virus long terminal repeat promoter
in the region of the deleted E1 wild-type adenoviral
genes (AdV-tk) was produced by Advantagene. Control
adenoviral vector contained the LacZ gene (Ad.LacZ) in
the same position and was also produced by Advanta-
gene. AdV-tk was produced in accordance with good
manufacturing practices (21 CFR210 and 211). The vec-
tor has been characterized for purity and potency and
approved for clinical use. The viral particle/infectious
unit (IU) ratio was 10:1. Animals bearing TC1 tumors
were treated with intratumoral (i.t.) injections of 1x1010
viral particles (vp) of AdV-tk or Ad.LacZ. After 48
hours, ganciclovir therapy was begun. The replication
deficient serotype 5 adenovirus encoding a hybrid IFN-
α2α1 (Ad.IFNα) with activity in mice was received from
Schering-Plough, Inc. Mice were treated with one dose
of Ad.IFNα i.t. at 1 x 109 pfu. Vectors were used at this
dosage in all experiments.
Chemotherapy
Ganciclovir (GCV) was purchased from Roche Laboratories
Inc. (Nutley, NJ) and was administered intraperitoneally at
50 mg/kg, once per day for five days, beginning at 2 days
following intratumoral AdV-tk injection. GCV was dosed
at 35 mg/kg post-operatively. GCV was suspended in
200μL normal saline for i.p. injections.Animal flank tumor models
Mice were injected subcutaneously (s.c.) on the right
flank with 1 x 106 of TC1 or 2x106 LKR tumor cells in
the appropriate mouse strain. 1.2x106 of TC1 were
injected s.c. into the flanks of syngeneic C57BL/6 mice.
Mice were treated in one of four groups: (a) Control re-
ceiving normal saline or Ad.LacZ, (b) Normal saline or
Ad.LacZ followed by surgery, (c) AdV-tk/GCV or Ad.
IFNα, and (d) AdV-tk/GCV or Ad.IFNα. Surgery
(described below) followed 3 to 5 after treatment com-
pletion. All experiments had at least five mice per group
and were repeated at least once.
Surgery
Two surgical models of cancer recurrence following sur-
gery were utilized. Briefly, mice bearing flank tumors
were anesthetized using intramuscular ketamine (80 mg/
kg) and xyalazine (10 mg/kg) then shaved with hair clip-
pers. A 1 to 2 cm incision was made immediately adja-
cent to the tumor. Resections were completed using
standard blunt dissection. To produce a local recurrence,
approximately 10% of the TC1 tumor burden was left at
the tumor margin. Careful consideration was given to
preserve blood supply to the remaining tumor volume.
Occasionally it was necessary to remove skin that was
adherent to the tumor. For the systemic recurrence
model, the entire LKR flank tumor was completely
resected (this was when pulmonary metastases were
known to be present). Skin closure was performed using
sterile silk 4-0 sutures. Buprenorphine (0.2 mg/kg) was
administered at the time of surgery and 6 hours after as
postoperative analgesia. Preoperative treatment was un-
known to the investigator performing surgery and mak-
ing tumor measurements. The Animal Use Committee
of the University of Pennsylvania and the Wistar Insti-
tute approved all protocols in compliance with the
Guide for the Care and Use of Laboratory Animals.
Immunohistochemical studies
Mice were euthanized at the time tumors were harvested
and frozen in Tissue-Tek OCT compound (Sakura Fine-
tek USA, Inc., Torrance, CA) to be stored at −80°C.
Five-micrometer sections were cut. Monoclonal anti-
bodies against CD8 cells (anti-CD8) were obtained from
BD Biosciences and immunohistochemical staining was
performed according to established protocols. Tumor
cell infiltrate was quantified by counting the number of
positively staining cells in four high-powered (×400)
fields. Five slides for each specimen were analyzed.
Flow cytometric analysis
For flow cytometric analysis, tumors were removed from
euthanized mice and minced into fine pieces in digestion
buffer containing 0.1 mg/mL DNase I and 2.0 mg/mL
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incubated in digestion buffer at 37°C for 30 minutes, fil-
tered through a 70-μm filter, and washed twice with R10.
Fc receptors were blocked with anti-mouse CD16/CD32
antibodies (BD Biosciences PharMingen). Following one
wash with PBS plus 2% FBS (staining buffer), cells were
incubated for 30 minutes at 4°C with appropriate antibodies
obtained from BD Biosciences PharMingen (San Diego,
CA) and used at the indicated dilutions for flow cytometry:
CD45-PerCP (1:200), CD8-APC (1:200), and CD11b-PerCP
(1:200), Ly6G-PE (1:200), Ly6C-APC (1:200). Samples were
then washed and resuspended in staining buffer or fixed in
2% paraformaldehyde. Splenocytes and lymph nodes were
studied by FACS analysis. All fluorescently labeled anti-
bodies used were purchased from BD Biosciences, except
F4/80-APC and GR1-FITC (obtained from eBioscience).
Flow cytometry was completed using a Becton Dickinson
FACS Calibur flow cytometer (San Jose, CA), and analyzed
using FlowJo software (Ashland, OR).
Functional in vivo lymphocyte killing assay
To determine the amount of suppressive activity found in
splenocytes from animals bearing large tumors, we used a
modification of an in vivo tumor neutralization assay [24].
Briefly, CD8 T-cells or CD11cells were isolated from the
spleens of mice using the MACS system (Miltenyi Biotec,
Auburn, CA). These CD8 T lymphocytes were mixed with
viable TC1 tumor cells in ratios of three purified CD8 sple-
nocytes to each tumor cell (3:1). The mixture (containing
0.5×106 TC1 cells and 1.5× 106 CD8 T-cells) was inocu-
lated into the flanks of naïve mice. This ratio of CD8 T-
cells and tumor cells has previously been determined to be
optimal for detecting positive and negative effects [25].
When CD11b cells were used in a “mixing in vivo tumor
neutralization assay”, a tumor:CD8 T-cell:CD11b ratio of
1:3:10 was utilized. Tumor growth was measured for 8 to
10 days and expressed as the mean ± SE of at least five
mice per group.
Statistical analyses
For flow cytometry, immunohistochemistry, real time RT-
PCR and flank tumor volume studies comparing differ-
ences between two groups, we used unpaired Student’s t
tests. For studies comparing more than two groups,
ANOVA with appropriate post hoc testing (Bonferroni)
was implemented. Differences were considered significant
when p< 0.05. Data are presented as mean (standard
error), unless otherwise noted.
Additional file
Additional file 1: Figure S1. Flow cytometry tracing confirming
depletion of CD8 T-Cells from splenocyte populations in mice receiving
CD8 antibodies.Abbreviations
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